ALS TDI -The First Non Profit Biotech, A Hidden Investment Opportunity?

ALS, also known as Lou Gehrig’s disease is a neurodegeneration disorder similar to MS, but with no known treatment.  ALS Therapy Development Institute, is the first non-profit biotech seeking to find a treatment and potentially increase the quality of life for individuals living with this illness.
Founded in 1999 and based in Cambridge, Mass,  ALS TDI is on the fast track to finding a successful drug that works. OneMedRadio had the pleasure of sitting down with CEO and CSO, Dr. Steve Perrin to discuss this debilitating disease and why its important to move quickly in discovering a treatment.
Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment. Quite an opportunity.

for complete article, see link:
http://healthworkscollective.com/herinaayot/30988/als-tdi-first-non-profit-biotech-hidden-investment-opportunity?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+healthworkscollective_allposts+%28Healthworks+Collective%29